To include your compound in the COVID-19 Resource Center, submit it here.

Syros discontinues single agent tamibarotene

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) said only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to treat relapsed or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The data were presented at the American Society

Read the full 461 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE